Company: ANTX
Filing Date: 2025-03-25
Form Type: 10-K
Source: 0000950170-25-044366
Chunk: 41

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-03-25
Form: 10-K
Item: Item 16
Chunk 41
---
 Incorporated by Reference

    ExhibitNumber
     
    Description
     
    Form
     
    File No.
     
    Exhibit
     
    Filing Date

    10.16#
     
    Offer Letter by and between the Registrant and Joshua Eizen, dated September 19, 2022.
     
    10-Q
     
    001-41331
     
    10.1
     
    November 9, 2022

    10.17#*
     
    AN2 Therapeutics, Inc. 2024 Amended Non-Employee Director Compensation Policy

    10.18‡*
     
    Exclusive Patent License Agreement, dated October 10, 2023, by and between the Registrant and the University of Georgia Research Foundation, Inc

    19.1*
     
    AN2 Therapeutics, Inc. 2022 Insider Trading Policy

    23.1*
     
    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.

    24.1*
     
    Power of Attorney (incorporated by reference to the signature page to this Annual Report on Form 10-K.)

    31.1*
     
    ﻿Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

    31.2*
     
    ﻿Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

    32.1*†
     
    ﻿Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

    32.2*†
     
    ﻿Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

    97.1
     
    Compensation Recovery Policy.
     
    10-K
     
    001-413